{"doc_id": "si-2024-0458-reg-1", "parent_doc_id": "si-2024-0458", "section_id": "reg-1", "section_label": "Regulation 1.", "si_number": "S.I. No. 458 of 2024", "title": "“Principal Regulations” means the Medicinal Products (Prescription and Control", "year": 2024, "heading": "1. (1) These Regulations may be cited as the Medicinal Products", "text_raw": "1. (1) These Regulations may be cited as the Medicinal Products \n\n(Prescription and Control of Supply) (Amendment) (No. 4) Regulations 2024. \n\n(2) The collective citation “the Medicinal Products (Prescription and Control \n\nof Supply) Regulations 2003 to 2024” includes these Regulations.", "text_norm": "1 (1) regulation may cited medicinal product (prescription control supply) (amendment) (no 4) regulation 2024 (2) collective citation medicinal product (prescription control supply) regulation 2003 2024 includes regulation", "start_char": 620, "end_char": 910, "source_path": "downloads\\2024\\2024_0458.pdf", "extraction_method": "pdfminer", "checksum": "sha256:c63aa6a989ce19987f187022d2090333cd708a3fb78657d5644fc9c024b3d88d", "cross_refs": []}
{"doc_id": "si-2024-0458-reg-2", "parent_doc_id": "si-2024-0458", "section_id": "reg-2", "section_label": "Regulation 2.", "si_number": "S.I. No. 458 of 2024", "title": "“Principal Regulations” means the Medicinal Products (Prescription and Control", "year": 2024, "heading": "2. These Regulations shall come into operation on 16th September 2024.", "text_raw": "2. These Regulations shall come into operation on 16th September 2024.", "text_norm": "2 regulation shall come operation 16th september 2024", "start_char": 910, "end_char": 983, "source_path": "downloads\\2024\\2024_0458.pdf", "extraction_method": "pdfminer", "checksum": "sha256:c63aa6a989ce19987f187022d2090333cd708a3fb78657d5644fc9c024b3d88d", "cross_refs": []}
{"doc_id": "si-2024-0458-reg-3", "parent_doc_id": "si-2024-0458", "section_id": "reg-3", "section_label": "Regulation 3.", "si_number": "S.I. No. 458 of 2024", "title": "“Principal Regulations” means the Medicinal Products (Prescription and Control", "year": 2024, "heading": "In these Regulations –", "text_raw": "3. \n\nIn these Regulations – \n\n“Principal Regulations” means the Medicinal Products (Prescription and Control \nof Supply) Regulations 2003 ( S.I. No. 540 of 2003); \n\n“Regulations of 2024” means the Medicinal Products (Prescription and Control \nof Supply) (No. 3) Regulations 2024 (S.I. No. 162 of 2024).", "text_norm": "3 regulation - principal regulation mean medicinal product (prescription control supply) regulation 2003 ( s.i no 540 2003) regulation 2024 mean medicinal product (prescription control supply) (no 3) regulation 2024 (s.i no 162 2024)", "start_char": 983, "end_char": 1288, "source_path": "downloads\\2024\\2024_0458.pdf", "extraction_method": "pdfminer", "checksum": "sha256:c63aa6a989ce19987f187022d2090333cd708a3fb78657d5644fc9c024b3d88d", "cross_refs": []}
{"doc_id": "si-2024-0458-reg-4", "parent_doc_id": "si-2024-0458", "section_id": "reg-4", "section_label": "Regulation 4.", "si_number": "S.I. No. 458 of 2024", "title": "“Principal Regulations” means the Medicinal Products (Prescription and Control", "year": 2024, "heading": "4. Regulation 10A of the Principal Regulations is amended –", "text_raw": "4. Regulation 10A of the Principal Regulations is amended – \n\n(a) \n\nby deleting paragraph (1)(g), \n\n(b) by substituting for paragraph (1)(h) the following: \n\n“(g) confirmation that prior to the administration of the product, \n\nconsent was — \n\n(i) \n\n(ii) \n\nobtained from the person to whom the product was \nadministered, or \n\nif he or she was unable to give such consent, the will \nand preferences of the person was established and the \nadministration was for the benefit of the person, or \n\n(iii) \n\nin the case of a child under 16 years of age, informed \nconsent was obtained from a parent or guardian.”, \n\n(c) \n\nby substituting for paragraph (2) the following: \n\n“(2) An authorised person who administers a medicinal product \nto a person pursuant to Regulation 4B shall, within 7 days \nof the administration, forward, by electronic means or \notherwise, a copy of the particulars, entered in the register \nrespect of such \nreferred \n\nin paragraph \n\n(1) \n\nin \n\nto \n\nNotice of the making of this Statutory Instrument was published in \n\"Iris Oifigiúil\" of 13th September, 2024. \n\n \n \n \n \n \n \n \n\f[458] 3 \n\nadministration, to the Health Service Executive (except in \nthe case of epinephrine (adrenaline), glucagon, glyceryl \ntrinitrate, naloxone or salbutamol).”, \n\n(d) by substituting for paragraph (3) the following: \n\n“(3) A pharmacy owner (including any successor pharmacy \nowner to the first-mentioned pharmacy owner) shall \npreserve, or cause to be preserved, and keep readily \navailable for inspection, in electronic form, an entry made \nin a register kept pursuant to paragraph (1) at the premises \nof the retail pharmacy business, for a period of two years \nfrom the date of the supply and administration of the \nmedicinal product”, and \n\n(e) \n\nby deleting paragraph (4).", "text_norm": "4 regulation 10a principal regulation amended - (a) deleting paragraph (1)(g) (b) substituting paragraph (1)(h) following (g) confirmation prior administration product consent -- (i) (ii) obtained person product administered unable give consent preference person established administration benefit person (iii) case child 16 year age informed consent obtained parent guardian (c) substituting paragraph (2) following (2) authorised person administers medicinal product person pursuant regulation 4b shall within 7 day administration forward electronic mean otherwise copy particular entered register respect referred paragraph (1) notice making statutory instrument published iris oifigiuil 13th september 2024 458 3 administration health service executive (except case epinephrine (adrenaline) glucagon glyceryl trinitrate naloxone salbutamol) (d) substituting paragraph (3) following (3) pharmacy owner (including successor pharmacy owner first-mentioned pharmacy owner) shall preserve cause preserved keep readily available inspection electronic form entry made register kept pursuant paragraph (1) premise retail pharmacy business period two year date supply administration medicinal product (e) deleting paragraph (4)", "start_char": 1288, "end_char": 3066, "source_path": "downloads\\2024\\2024_0458.pdf", "extraction_method": "pdfminer", "checksum": "sha256:c63aa6a989ce19987f187022d2090333cd708a3fb78657d5644fc9c024b3d88d", "cross_refs": []}
{"doc_id": "si-2024-0458-reg-5", "parent_doc_id": "si-2024-0458", "section_id": "reg-5", "section_label": "Regulation 5.", "si_number": "S.I. No. 458 of 2024", "title": "“Principal Regulations” means the Medicinal Products (Prescription and Control", "year": 2024, "heading": "5. Regulation 10C of the Principal Regulations is amended by substituting", "text_raw": "5. Regulation 10C of the Principal Regulations is amended by substituting \n\nfor paragraph (1)(c) the following: \n\n“(c) confirmation that prior to the administration of the product – \n\n(i) Consent was obtained from the person to whom the product \n\nwas administered, or \n\n(ii) \n\nif he or she was unable to give such consent, the will and \npreferences of the person was established and the \nadministration was for the benefit of the person, or \n\n(iii) \n\nin the case of a child under 16 years of age, informed \nconsent was obtained from a parent or guardian;”.", "text_norm": "5 regulation 10c principal regulation amended substituting paragraph (1)(c) following (c) confirmation prior administration product - (i) consent obtained person product administered (ii) unable give consent preference person established administration benefit person (iii) case child 16 year age informed consent obtained parent guardian", "start_char": 3066, "end_char": 3625, "source_path": "downloads\\2024\\2024_0458.pdf", "extraction_method": "pdfminer", "checksum": "sha256:c63aa6a989ce19987f187022d2090333cd708a3fb78657d5644fc9c024b3d88d", "cross_refs": []}
{"doc_id": "si-2024-0458-reg-6", "parent_doc_id": "si-2024-0458", "section_id": "reg-6", "section_label": "Regulation 6.", "si_number": "S.I. No. 458 of 2024", "title": "“Principal Regulations” means the Medicinal Products (Prescription and Control", "year": 2024, "heading": "6. Regulation 10D of the Principal Regulations is amended –", "text_raw": "6. Regulation 10D of the Principal Regulations is amended – \n\n(a) \n\nby substituting for paragraph (c) the following: \n\n“(c) confirmation that prior to the administration of the \n\nproduct— \n\n(i) \n\n(ii) \n\nconsent was obtained from the person to whom the \nproduct was administered for its administration, or \n\nif he or she was unable to give such consent, the will \nand preferences of the person was established and the \nadministration was for the benefit of the person, or \n\n(iii) \n\nin the case of a child under 16 years of age, informed \nconsent was obtained from a parent or guardian;” \n\n(b) by deleting paragraph (g) and consequently re-numbering \n\nparagraph (h) as paragraph (g). \n\n \n \n \n \n \n\f4 [458]", "text_norm": "6 regulation 10d principal regulation amended - (a) substituting paragraph (c) following (c) confirmation prior administration product-- (i) (ii) consent obtained person product administered administration unable give consent preference person established administration benefit person (iii) case child 16 year age informed consent obtained parent guardian (b) deleting paragraph (g) consequently re-numbering paragraph (h) paragraph (g) 4 458", "start_char": 3625, "end_char": 4330, "source_path": "downloads\\2024\\2024_0458.pdf", "extraction_method": "pdfminer", "checksum": "sha256:c63aa6a989ce19987f187022d2090333cd708a3fb78657d5644fc9c024b3d88d", "cross_refs": []}
{"doc_id": "si-2024-0458-reg-7", "parent_doc_id": "si-2024-0458", "section_id": "reg-7", "section_label": "Regulation 7.", "si_number": "S.I. No. 458 of 2024", "title": "“Principal Regulations” means the Medicinal Products (Prescription and Control", "year": 2024, "heading": "7. The Eighth Schedule (as amended by Regulation 3 of the 2024", "text_raw": "7. The Eighth Schedule (as amended by Regulation 3 of the 2024 \nRegulations) to the Principal Regulations is amended by inserting the following \nentry: \n\n“ \n\nMedicinal \nproduct \n\nRoute of \nadministration \n\nForm and \npresentation \nof the \nproduct \nadministered \n\nIndication \nfor which \nthe \nmedicinal \nproduct may \nbe \nadministered \n\nDosage and \nconditions of \nadministration \n\nPlace of \nadministration \n\nColumn 1 \n\nColumn 2 \n\nColumn 3 \n\nColumn 4 \n\nColumn 5 \n\nColumn 6 \n\nDispersion \nfor injection \n\nIntramuscular \ninjection \n\nComirnaty JN.1 \n30 \nmicrograms/dose \ndispersion for \ninjection \n\nDispersion \nfor injection \n\nIntramuscular \ninjection \n\nComirnaty JN.1 \n10 \nmicrograms/dose \ndispersion for \ninjection \n\nConcentrate \nfor dispersion \nfor injection \n\nIntramuscular \ninjection \n\nComirnaty JN.1 \n3 \nmicrograms/dose \nconcentrate for \ndispersion for \ninjection \n\n” \n\nIndicated for \nactive \nimmunisation \nto prevent \nCOVID-19 \ncaused by \nSARS-CoV2, in \nindividuals \n12 years of \nage and older \n\nIndicated for \nactive \nimmunisation \nto prevent \nCOVID-19 \ncaused by \nSARS-CoV2, in children \naged 5 to 11 \nyears. \n\nIndicated for \nactive \nimmunisation \nto prevent \nCOVID-19 \ncaused by \nSARS-CoV2, in infants \nand children \naged 6 \nmonths to 4 \nyears. \n\nAny suitable \nand appropriate \nplace, having \nregard to public \nconvenience \nand the need to \nprotect the \nhealth and \nsafety of the \npublic and \nsafely \nadminister the \nproduct. \n\nAny suitable \nand appropriate \nplace, having \nregard to public \nconvenience \nand the need to \nprotect the \nhealth and \nsafety of the \npublic and \nsafely \nadminister the \nproduct. \n\nAny suitable \nand appropriate \nplace, having \nregard to public \nconvenience \nand the need to \nprotect the \nhealth and \nsafety of the \npublic and \nsafely \nadminister the \nproduct. \n\nIn accordance \nwith the \nsummary of \nproduct \ncharacteristics \nand the relevant \nrecommendations \nor guidelines \nissued by the \nNational \nImmunisation \nAdvisory \nCommittee and \naccepted by the \nMinister for \nHealth. \n\nIn accordance \nwith the \nsummary of \nproduct \ncharacteristics \nand the relevant \nrecommendations \nor guidelines \nissued by the \nNational \nImmunisation \nAdvisory \nCommittee and \naccepted by the \nMinister for \nHealth. \n\nIn accordance \nwith the \nsummary of \nproduct \ncharacteristics \nand the relevant \nrecommendations \nor guidelines \nissued by the \nNational \nImmunisation \nAdvisory \nCommittee and \naccepted by the \nMinister for \nHealth. \n\n \n \n \n \n \n \n \n \n\f[458] 5", "text_norm": "7 eighth schedule (as amended regulation 3 2024 regulations) principal regulation amended inserting following entry medicinal product route administration form presentation product administered indication medicinal product may administered dosage condition administration place administration column 1 column 2 column 3 column 4 column 5 column 6 dispersion injection intramuscular injection comirnaty jn.1 30 microgram dose dispersion injection dispersion injection intramuscular injection comirnaty jn.1 10 microgram dose dispersion injection concentrate dispersion injection intramuscular injection comirnaty jn.1 3 microgram dose concentrate dispersion injection indicated active immunisation prevent covid-19 caused sars-cov2 individual 12 year age older indicated active immunisation prevent covid-19 caused sars-cov2 child aged 5 11 year indicated active immunisation prevent covid-19 caused sars-cov2 infant child aged 6 month 4 year suitable appropriate place regard public convenience need protect health safety public safely administer product suitable appropriate place regard public convenience need protect health safety public safely administer product suitable appropriate place regard public convenience need protect health safety public safely administer product accordance summary product characteristic relevant recommendation guideline issued national immunisation advisory committee accepted minister health accordance summary product characteristic relevant recommendation guideline issued national immunisation advisory committee accepted minister health accordance summary product characteristic relevant recommendation guideline issued national immunisation advisory committee accepted minister health 458 5", "start_char": 4330, "end_char": 6802, "source_path": "downloads\\2024\\2024_0458.pdf", "extraction_method": "pdfminer", "checksum": "sha256:c63aa6a989ce19987f187022d2090333cd708a3fb78657d5644fc9c024b3d88d", "cross_refs": []}
{"doc_id": "si-2024-0458-reg-8", "parent_doc_id": "si-2024-0458", "section_id": "reg-8", "section_label": "Regulation 8.", "si_number": "S.I. No. 458 of 2024", "title": "“Principal Regulations” means the Medicinal Products (Prescription and Control", "year": 2024, "heading": "8. The Twelfth Schedule (as amended by Regulation 5 of the 2024", "text_raw": "8. The Twelfth Schedule (as amended by Regulation 5 of the 2024 \nRegulations) to the Principal Regulations is amended by inserting the following \nentry: \n\n“ \n\nMedicinal \nproduct \n\nForm and \npresentation of \nproduct \nadministered \n\nRoute of \nadministration \n\nIndication for which \nthe medicinal product \nmay be administered \n\nDosage and conditions \nof administration \n\nColumn 1 \n\nColumn 2 \n\nColumn 3 \n\nColumn 4 \n\nColumn 5 \n\nDispersion for \ninjection \n\nIntramuscular \ninjection \n\nComirnaty JN.1 \n30 \nmicrograms/dose \ndispersion for \ninjection \n\nIndicated for active \nimmunisation to \nprevent COVID-19 \ncaused by SARS-CoV2, in individuals 12 \nyears of age and older \n\nDispersion for \ninjection \n\nIntramuscular \ninjection \n\nComirnaty JN.1 \n10 \nmicrograms/dose \ndispersion for \ninjection \n\nIndicated for active \nimmunisation to \nprevent COVID-19 \ncaused by SARS-CoV2, in children aged 5 to \n11 years. \n\nComirnaty JN.1 3 \nmicrograms/dose \nconcentrate for \ndispersion for \ninjection \n\nConcentrate for \ndispersion for \ninjection \n\nIntramuscular \ninjection \n\nIndicated for active \nimmunisation to \nprevent COVID-19 \ncaused by SARS-CoV2, in infants and \nchildren aged 6 months \nto 4 years. \n\nIn accordance with the \nsummary of product \ncharacteristics and the \nrelevant \nrecommendations or \nguidelines issued by \nthe National \nImmunisation Advisory \nCommittee and \naccepted by the \nMinister for Health. \n\nIn accordance with the \nsummary of product \ncharacteristics and the \nrelevant \nrecommendations or \nguidelines issued by \nthe National \nImmunisation Advisory \nCommittee and \naccepted by the \nMinister for Health. \n\nIn accordance with the \nsummary of product \ncharacteristics and the \nrelevant \nrecommendations or \nguidelines issued by \nthe National \nImmunisation Advisory \nCommittee and \naccepted by the \nMinister for Health. \n\n” \n\nGIVEN under my Official Seal, \n\n11 September, 2024. \n\nSTEPHEN DONNELLY, \nMinister for Health. \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\f6 [458]", "text_norm": "8 twelfth schedule (as amended regulation 5 2024 regulations) principal regulation amended inserting following entry medicinal product form presentation product administered route administration indication medicinal product may administered dosage condition administration column 1 column 2 column 3 column 4 column 5 dispersion injection intramuscular injection comirnaty jn.1 30 microgram dose dispersion injection indicated active immunisation prevent covid-19 caused sars-cov2 individual 12 year age older dispersion injection intramuscular injection comirnaty jn.1 10 microgram dose dispersion injection indicated active immunisation prevent covid-19 caused sars-cov2 child aged 5 11 year comirnaty jn.1 3 microgram dose concentrate dispersion injection concentrate dispersion injection intramuscular injection indicated active immunisation prevent covid-19 caused sars-cov2 infant child aged 6 month 4 year accordance summary product characteristic relevant recommendation guideline issued national immunisation advisory committee accepted minister health accordance summary product characteristic relevant recommendation guideline issued national immunisation advisory committee accepted minister health accordance summary product characteristic relevant recommendation guideline issued national immunisation advisory committee accepted minister health given official seal 11 september 2024 stephen donnelly minister health 6 458", "start_char": 6802, "end_char": 8764, "source_path": "downloads\\2024\\2024_0458.pdf", "extraction_method": "pdfminer", "checksum": "sha256:c63aa6a989ce19987f187022d2090333cd708a3fb78657d5644fc9c024b3d88d", "cross_refs": []}
{"doc_id": "si-2024-0458-explanatory-note", "parent_doc_id": "si-2024-0458", "section_id": "explanatory-note", "section_label": "EXPLANATORY NOTE", "si_number": "S.I. No. 458 of 2024", "title": "“Principal Regulations” means the Medicinal Products (Prescription and Control", "year": 2024, "heading": "(This note is not part of the Instrument and does not purport to be a legal", "text_raw": "EXPLANATORY NOTE \n\n(This note is not part of the Instrument and does not purport to be a legal \ninterpretation.) \n\nThese Regulations amend the Medicinal Products (Prescription and Control of \nSupply) Regulations 2003. \n\nThe purpose of these Regulations is to align the consent requirements in relation \nto the provision of vaccinations and certain emergency medicines. These \nRegulations also update the requirements regarding the keeping of records in \nrelation to the supply and administration of medicinal products pursuant to \nRegulation 4B of the Medicinal Products (Prescription and Control of Supply) \nRegulations 2003. The relevant schedules in relation to the COVID-19 vaccines \nare updated to include the Comirnaty JN.1 COVID-19 vaccine. \n\nThese Regulations may be cited as the Medicinal Products (Prescription and \nControl of Supply) (Amendment) (No. 4) Regulations 2024. \n\n \n \n \n \n \n \n \n\f[458] 7 \n\nBAILE ÁTHA CLIATH \nARNA FHOILSIÚ AG OIFIG AN tSOLÁTHAIR \nLe ceannach díreach ó \nFOILSEACHÁIN RIALTAIS, \nBÓTHAR BHAILE UÍ BHEOLÁIN, \nCILL MHAIGHNEANN, \nBAILE ÁTHA CLIATH 8, \nD08 XAO6 \n\nTeil: 046 942 3100 \nr-phost: publications@opw.ie \n—————— \n\nDUBLIN \nPUBLISHED BY THE STATIONERY OFFICE \nTo be purchased from \nGOVERNMENT PUBLICATIONS, \nMOUNTSHANNON ROAD, \nKILMAINHAM, DUBLIN 8, \nD08 XAO6 \n\nTel: 046 942 3100 \nE-mail: publications@opw.ie \n—————— \n\n€ 3.00 \n\n(DH-545) 30. 9/24. Propylon.", "text_norm": "explanatory note (this note part instrument purport legal interpretation.) regulation amend medicinal product (prescription control supply) regulation 2003 purpose regulation align consent requirement relation provision vaccination certain emergency medicine regulation also update requirement regarding keeping record relation supply administration medicinal product pursuant regulation 4b medicinal product (prescription control supply) regulation 2003 relevant schedule relation covid-19 vaccine updated include comirnaty jn.1 covid-19 vaccine regulation may cited medicinal product (prescription control supply) (amendment) (no 4) regulation 2024 458 7 baile atha cliath arna fhoilsiu ag oifig tsolathair le ceannach direach foilseachain rialtais bothar bhaile ui bheolain cill mhaighneann baile atha cliath 8 d08 xao6 teil 046 942 3100 r-phost publication opw.ie ------------ dublin published stationery office purchased government publication mountshannon road kilmainham dublin 8 d08 xao6 tel 046 942 3100 e-mail publication opw.ie ------------ eur 3.00 (dh-545) 30 9 24 propylon", "start_char": 8764, "end_char": 10157, "source_path": "downloads\\2024\\2024_0458.pdf", "extraction_method": "pdfminer", "checksum": "sha256:c63aa6a989ce19987f187022d2090333cd708a3fb78657d5644fc9c024b3d88d", "cross_refs": []}
